Pulmonary Embolism as an Initial Presentation of Adrenocortical Carcinoma.

World J Oncol

Box Hill Hospital, Eastern Health Victoria, Nelson Road, Box Hill, VIC 3128, Australia.

Published: June 2014

Adrenocortical carcinomas (ACCs) are rare and often aggressive with more than 50% of the cases already in stage III-IV (ENSAT) at the time of diagnosis. Nearly 60% of ACCs present with hormone overproduction syndromes (Cushing's syndrome and/or virilization), while the rest present with abdominal mass or incidental finding. Aggressive surgical resection is the mainstay of treatment usually followed by adjuvant mitotane monotherapy. For the advanced stage, adjuvant radiotherapy and combined chemotherapy with mitotane therapy can be added for survival benefit. Here, we would like to report a case of stage III high-grade ACC without syndromes of hormone overproduction, initially presented with pulmonary embolism. It was rapidly progressive with metastases to lungs, peritoneum and bone despite aggressive surgery followed by adjuvant mitotane monotherapy. However, after palliative radiotherapy to thoraco-lumbar spine for spinal cord compression, and adding chemotherapy (six cycles of EDP: etoposide, doxorubicin, cisplatin) to mitotane, a significant partial remission was achieved. He has had 24 months of progression-free survival, and is currently on mitotane monotherapy with cortisol replacement. Discussion will support multimodality therapy for stage III high-grade ACC with surgery immediately followed by adjuvant radiotherapy and combined chemotherapy with mitotane therapy to prevent local recurrence and distant metastases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649820PMC
http://dx.doi.org/10.14740/wjon814wDOI Listing

Publication Analysis

Top Keywords

mitotane monotherapy
12
pulmonary embolism
8
hormone overproduction
8
adjuvant mitotane
8
adjuvant radiotherapy
8
radiotherapy combined
8
combined chemotherapy
8
chemotherapy mitotane
8
mitotane therapy
8
stage iii
8

Similar Publications

Background: Adrenocortical carcinoma is a rare malignancy with poor response to systemic chemotherapy. Mitotane is the only approved therapy for adrenocortical carcinoma. Cabozantinib is a multikinase inhibitor approved in multiple malignancies.

View Article and Find Full Text PDF
Article Synopsis
  • Current treatments for metastatic adrenocortical carcinoma (ACC), like mitotane and cytotoxic agents, are not very effective, leading researchers to explore new options.* -
  • The study identified TAK-243, a novel inhibitor that works by disrupting protein ubiquitination, and it shows strong potential for killing ACC cells both alone and in combination with existing therapies.* -
  • TAK-243 demonstrated promising results in preclinical models, including patient-derived organoids and mouse studies, warranting further investigation in clinical trials for advanced-stage ACC patients.*
View Article and Find Full Text PDF

Treatment for advanced adrenocortical carcinoma (ACC) consists of mitotane alone or combined with etoposide, doxorubicin, and cisplatin (EDP). Although both therapies are widely used, markers of response are still lacking. Since inflammation-based scores have been proposed as prognostic factors in ACC, we aimed to investigate their role in predicting the response to first-line chemotherapy.

View Article and Find Full Text PDF

Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.

Curr Opin Urol

January 2023

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Purpose Of Review: Adrenocortical carcinoma (ACC) is a rare, aggressive disease with a paucity of data and great variability between published studies regarding its treatment. This review provides information on current clinical management and oncological and endocrine outcomes.

Recent Findings: Complete surgical resection is the only potentially curative treatment for adrenocortical carcinoma (ACC).

View Article and Find Full Text PDF

Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of Experience.

J Endocr Soc

September 2022

Department of Oncology, Sharett institute for Oncology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

Context: Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis for both locally advanced and metastatic disease. Standard treatment with combination etoposide-doxorubicin-cisplatin-mitotane (EDP-M) is highly toxic and some patients benefit from mitotane monotherapy. However, identification of these patients remains challenging.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!